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Abstract
Background: Human papillomavirus (HPV) vaccination is safe and effective in preventing cervical cancer in females.
As HPV infections can also induce cancers of the anus, penis and oral cavity, male vaccination is also advocated, but
systematic reviews on efficacy and safety in males are lacking.
Methods: We performed a systematic review on the efficacy, effectiveness and safety of HPV vaccination in males
of any age. MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were
searched from inception to April 2017.
Results: We identified 5196 articles and seven studies (four randomized controlled trials (RCTs), three non-
randomized studies) were included, comprising a total of 5294 participants. Vaccine efficacy against at least
6-month persisting anogenital HPV 16 infections was 46.9% (95% confidence interval (CI) 28.6–60.8%), whereas
efficacy against persisting oral infections was 88% (2–98%). A vaccine efficacy of 61.9% (21.4–82.8%) and 46.8%
(− 20 to –77.9%) was observed against anal intraepithelial neoplasia grade 2 and grade 3 lesions, respectively. No
meaningful estimates were available on vaccine efficacy or effectiveness against penile intraepithelial neoplasia
grade 2 or 3, and no data were identified for anal, penile or head and neck squamous cell cancer. In participants
who were HPV-seronegative and PCR-negative at enrolment, efficacy against all outcomes was higher as compared
to seropositive and/or PCR-positive individuals. Risk of bias was low in three RCTs and high in one, while the three
non-randomized studies were at serious to critical risk of bias. Grading of Recommendations Assessment,
Development and Evaluation evidence quality was moderate to low for most outcomes.
Conclusions: HPV vaccination in males is moderately effective against persistent anogenital HPV infection and
high-grade anal intraepithelial lesions in studies where the population consists mainly of HPV-infected males.
Vaccine effectiveness was high in study groups comprising HPV-naïve males. This supports a recommendation
for vaccination of boys before the onset of sexual activity with the goal of establishing optimal vaccine-induced
protection. Mathematical modelling studies will still be needed to assess the effects of adding males to existing
HPV vaccination programs in females.
Trial registration: Prospective Register for Systematic Reviews (PROSPERO) registration CRD42016038965.
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Background
Human papillomavirus (HPV) is the most common
sexually transmitted microorganism. The skin and mu-
cosa of the anogenital tract, oral cavity, oropharynx and
larynx are frequently affected by this virus [1]. The initial
HPV infection is asymptomatic, and the virus is cleared
in the majority of cases [2, 3]. About 10% of HPV infec-
tions persist, and less than 3% result in epithelial dyspla-
sia or even cancer (1%) if the infection is due to an
oncogenic HPV type [4–6]. Presently, more than 200 dif-
ferent HPV types have been described. They are classi-
fied as high risk (HR) and low risk (LR) viruses. While
LR types such as HPV 6 and HPV 11 can cause genital
warts, infections due to HR HPV types can induce can-
cer. The International Agency for Research on Cancer
(IARC) classifies 12 HPV types as HR cancer-causing
types, of which HPV 16 and HPV 18 are the most com-
mon [7, 8]. In females, nearly 100% of cervical cancers
are attributable to HR HPV types [9]. In males, approxi-
mately 33% of penile cancers and up to 90% of anal can-
cers are attributed to HR HPV infections, primarily with
HPV type 16 [10–12]. The HPV attributable fraction in
cancers of the oral cavity, oropharynx and larynx was es-
timated to be 22.4%, 4.4% and 3.5%, respectively [13].
Anogenital HPV infections are common in men. In a
population-based survey in the USA, 23% of participants
had a penile infection with a high-risk HPV type [14]. In
men who have sex with men (MSM) and in HIV-positive
men, even higher prevalences were observed. A Dutch
study reported that 45% of HIV-negative MSM and 65%
of HIV-positive MSM had an anal infection by a high--
risk HPV type [15]. HPV infections of the oral cavity are
less prevalent: a systematic review reported a pooled
prevalence of 4.5%, with no significant differences between
men and women [16]. According to the German Centre
for Cancer Registry Data, in 2013 a total of 1358 male
cancer cases in Germany were attributable to HPV [17].
The life-time risk of HPV-associated genital warts has
been estimated to be 5–10% [18].
To date, three different vaccines against HPV have been
licensed [19]. They contain virus-like particles (VPLs) that
induce immunity against certain HPV types. The bivalent
vaccine protects against HR HPV types 16 and 18, and the
quadrivalent vaccine protects against HR HPV types 16
and 18 as well as LR HPV types 6 and 11. A nonavalent
vaccine was approved by the US and European regulatory
authorities in 2015 and 2016, respectively, adding protec-
tion against five additional HR HPV types. Based on epi-
demiological data, it has been estimated that 85–90% of
all cervical cancer cases could be prevented by vaccin-
ation with the nonavalent HPV vaccine if it is adminis-
tered to girls before their sexual debut [20]. By
targeting HPV 16 and 18 alone, 60–70% of all cervical
cancers could be prevented.
While most industrialized countries have introduced
routine female HPV vaccination into their national
immunization programs, routine vaccination of boys and
men is currently implemented in only a few countries,
such as Australia, Canada, the USA and Austria. Vaccin-
ation of boys and men may further reduce the incidence
of cervical cancer and its precursors via herd protection,
and reduce the incidence of anal and penile as well as
head and neck cancers [21, 22]. The aim of this system-
atic review was to assess the currently available evidence
on the efficacy, effectiveness and safety of HPV vaccin-
ation in males.
Methods
Search strategy and selection criteria
This systematic review followed a protocol published
in the Prospective Register for Systematic Reviews
(PROSPERO; registration no. CRD42016038965) and
was reported according to the guidelines in the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) statement [23]. To be eligible, a study had to in-
vestigate the efficacy, effectiveness and/or safety of vaccin-
ation (with a licensed vaccine) against HPV in males of any
age. The control group had to be males who were either
unvaccinated or had received placebo or a vaccine not di-
rected against HPV. An eligible study had to report on at
least one of the following predefined outcomes: (1) incident
oral infection with an HR HPV type; (2) incident anogenital
(or anal) infection with an HR HPV type; (3) persisting oral
infection with an HR HPV type (≥ 6 months); (4) per-
sisting anogenital (or anal) infection with an HR HPV
type (≥ 6 months); (5) condyloma acuminatum (genital
or anal) due to HPV 6 or 11; (6) anal intraepithelial
neoplasia (AIN) grade 2; (7) AIN grade 3 or carcinoma;
(8) penile intraepithelial neoplasia (PIN) grade 2; (9)
PIN grade 3 or carcinoma; (10) squamous cell carcin-
oma of the head and neck region, including the oro-
pharynx, larynx and oral cavity; (11) epithelial dysplasia
related to (10); and (12) any severe adverse event fol-
lowing immunization. As we were primarily interested
in clinical relevance, we did not restrict ourselves to
vaccine-type specific lesions only.
The electronic databases searched were MEDLINE,
Embase and the Cochrane Central Register of Controlled
Trials (date of initial search 4 November 2016; last update
18 April 2017). For details on the complete search strategy,
see Additional file 1. Additionally, ClinicalTrials.gov was
searched systematically for unpublished or ongoing trials.
Electronic searches were complemented by manually
screening conference abstract books of major inter-
national HPV conferences (EUROGIN 2016, Inter-
national HPV Conference 2017) as well as reference
lists of all identified studies and those of identified re-
views. Search results (titles, abstracts, full texts) were
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independently assessed by two investigators (TH, MWP).
Differences were discussed until a consensus was reached.
We did not make any restrictions with regard to setting,
language or publication status (published/unpublished).
Potential indirect effects of male HPV vaccination on the
incidence of clinical outcomes in females were not con-
sidered in this review.
Data extraction
From the eligible studies, two independent reviewers
(TH, MWP) used standardized forms to extract study
characteristics and assess methodological quality. In case
of disagreement, a final decision was made by consensus.
The corresponding authors or principal investigators of
three studies were contacted for additional data and in-
formation [24–26]. The following data were extracted:
study location, study design, study period, inclusion cri-
teria, exclusion criteria, age at enrolment, duration of
follow-up, vaccine used, comparator, study sponsorship,
conflict of interests, number (proportion) of vaccinated
participants with outcome, number (proportion) of con-
trol participants with outcome, unadjusted estimates, ad-
justed estimates, confounders.
Assessment of risk of bias and quality of evidence
For randomized controlled trials (RCTs), the Cochrane
risk of bias tool was used to assess the following do-
mains: random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective
reporting, other bias [27]. Studies were categorized as
being at “high risk”, “low risk” or “unclear risk” of bias.
For non-randomized studies, the Risk Of Bias in
Non-randomized Studies - of Interventions (ROBINS-I)
tool was used, comprising the following domains: bias
due to confounding, bias in selection of participants
into the study, bias in classification of interventions,
bias due to deviations from intended interventions, bias
due to missing data, bias in measurement of outcomes,
bias in selection of the reported results [28]. Risk of
bias was categorized as being “low risk”, “moderate
risk”, “serious risk” or “critical risk”.
The methodology of the Grading of Recommenda-
tions, Assessment, Development and Evaluation (GRADE)
working group was used to assess the quality of the
evidence [29, 30].
Statistical analysis
Abstracted data were aggregated in tables. Risk ratios,
odds ratios, risk differences and corresponding 95% con-
fidence intervals (95% CI) were either calculated or ex-
tracted from the publications. Vaccine efficacy and
vaccine effectiveness were either extracted from the pub-
lications or calculated as [1-(risk ratio or rate ratio
comparing vaccine and control recipients)] × 100. Since
only one study per outcome and study design was iden-
tified in this review, no meta-analyses were performed.
According to the review protocol, analyses were per-
formed in two subgroups: (1) all study participants, irre-
spective of HPV infection at enrolment, and (2) study
participants who were seronegative and PCR-negative
for the relevant HPV types at enrolment.
Results
We identified a total of 5196 entries in electronic data-
bases. After exclusion of duplicates, 3318 articles
remained for title screening. Of these, 3065 papers were
judged to be irrelevant according to their titles and were
excluded. The abstracts of the remaining 253 publica-
tions were subsequently screened, and 167 of them were
considered irrelevant and therefore excluded. We then
assessed the full text of the remaining 86 articles. Of
these, 79 were excluded due to lack of relevant data
(n = 16), lack of data on men (n = 14), being a model-
ling study (n = 1), being a conference abstract of an in-
cluded study (n = 3), lack of comparator (n = 16), lack
of original data (n = 22) or not being a vaccination
study (n = 7). Thereby, we finally included seven studies in
the analysis (for details, see Fig. 1). Bibliographic data of
the 79 studies that were excluded after full-text assess-
ment are reported in Additional file 2.
We included four RCTs [26, 31–33] and three non-
randomized studies [24, 25, 34]. The studies comprised
data of a total of 5294 study participants. One included
RCT [33] was a subtrial of another included study [32],
but it reported different outcomes. The main study char-
acteristics are shown in Table 1. Three of these trials
were international multicentre studies [26, 32, 33], while
the remaining four studies were performed solely in the
USA or in Turkey. Four of the studies included both
heterosexual men and MSM [25, 32–34]. One study in-
cluded only self-identified heterosexual men [31]. The
other two studies recruited male and female participants,
but only the results for males are reported here. One of
these studies was performed in adolescents and young
adults with behaviorally acquired HIV [24], whereas
the other one included HIV-positive adults [26]. The
age of the participants at study entry ranged from 12
to 76 years. In all studies, the quadrivalent vaccine
(Gardasil) was used. Six studies provided information
on potential conflicts of interest [24–26, 32–34]. Two
studies were registrative studies and reported sponsor-
ship by a pharmaceutical company [32, 33].
Only two of the studies reported data on HPV-naïve
participants [32, 33]. These studies were registrative tri-
als and comprised a total of 2032 participants in the vac-
cinated and 2033 participants in the placebo arm. Of
those, 1397 subjects in the vaccinated and 1408 in the
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placebo group were HPV-naïve men. The mean age in
the vaccinated group was 20.6 years (standard deviation
(SD) 2.0; range 16–26 years); it was 20.5 years (SD 2.0;
range 15–27 years) in the placebo group. The median
length of follow-up was 2.9 years for both groups.
Of the 12 outcomes defined a priori in the review
protocol, ten were reported in the included studies
(Table 2). In two of the RCTs [32, 33], the primary effi-
cacy endpoints defined by the investigators were com-
pound endpoints comprising malignant and benign anal
or genital lesions, but only those data that correspond to
the outcomes predefined in our protocol were used for
the following analyses. We considered the outcome
“DNA detection” reported in these two trials [32, 33] as
being equivalent to “incident infection”. Furthermore,
because different sampling techniques were used, we
separated “anal infection” from “anogenital infection” in
these two studies [32, 33]. A total of four studies reported
data on condyloma acuminatum, while two studies re-
ported on the outcomes AIN grade 2, AIN grade 3 and/or
severe adverse events. For the remaining outcomes, only
one study per outcome was identified. We did not identify
any relevant studies investigating the outcomes 10 “squa-
mous cell carcinoma of the head and neck region” or 11
“epithelial dysplasia related to squamous cell carcinoma of
the head and neck region”.
Risk of bias was low in three of the RCTs (Table 3). In
the remaining RCT [31], risk of bias was judged to be high
due to the lack of a placebo-controlled study arm (con-
trols were unvaccinated). The three non-randomized
studies were judged to have a serious (two studies) or
critical risk of bias (one study) due to residual con-
founding, risk of selection bias and missing data
(Table 4).
Table 5 shows vaccine efficacy and effectiveness
against infection with HR HPV types (HPV 16 or HPV
18), irrespective of HPV infection status at enrolment.
Vaccine efficacy was low against incident anogenital in-
fections caused by HPV 16 (28%) and HPV 18 (33.9%),
but was higher against incident anal infections (45.1%
Fig. 1 Flow diagram
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against HPV 16; 49.5% against HPV 18), although the
95% CIs were overlapping. Vaccine efficacy estimates for
preventing persisting (defined as ≥ 6 months) anogenital
and anal infections were higher than those for incident
infections (46.9–73.6%). Two of the RCTs also reported
vaccine efficacy in participants who were seronegative
and PCR-negative for the respectively studied HPV types
at enrolment. As shown in Table 6, vaccine efficacy esti-
mates were higher for all outcomes compared with those
in the analyses performed irrespective of HPV status,
ranging from 41.1% (incident anogenital infection with
HPV 16) to 100% (incident and persisting anal infection
with HPV 18), with wide confidence intervals.
Incident oral infections with HR HPV types were inves-
tigated in only one study, which used a non-randomized
design. Here, a vaccine effectiveness of 91% was ob-
served; however, the 95% CI was very wide and no
confounder-adjusted estimate was reported. For per-
sistent oral HPV infections, an efficacy of 88% was
reported in one RCT (Table 5).
Estimates of vaccine efficacy and effectiveness against
anogenital lesions are shown in Tables 7 and 8. Efficacy
against genital condyloma acuminatum was investigated
in two of the RCTs: one RCT reported a vaccine efficacy
of 67.2%, whereas the other one did not show a protective
effect (− 26%). However, the latter RCT included only par-
ticipants with a history of condyloma and had a high risk
of bias. Efficacy and effectiveness against anal condyloma
was assessed in one RCT and in one non-randomized
study. Both studies reported very similar results (57.2%
and 55%, respectively), but their confidence intervals were
wide. Vaccine efficacy against AIN grade 2 was reported
to be 61.9% in one RCT, while vaccine effectiveness was
slightly lower in a non-randomized study (50%). AIN
grade 3 was investigated in only one RCT, which reported
a non-significant efficacy of 46.8%. Likewise, PIN grade 2
or 3 was reported in one RCT, but the number of cases
was too small in both the vaccinated (n = 3) and pla-
cebo groups (n = 2) to generate a meaningful estimate
of vaccine efficacy. Since no cases of anal cancer or
penile/perineal/perianal cancer were observed in the in-
cluded studies, efficacy or effectiveness against these
outcomes could not be calculated. Table 8 shows the
respective estimates for those RCT participants who
were HPV-negative at study entry [32, 33]. In this sub-
group, estimates of vaccine efficacy for the prevention
of anogenital lesions were higher than among individ-
uals irrespective of HPV status, but the case numbers
were small and did not lead to meaningful efficacy esti-
mates against AIN (grade 2: efficacy 75.8%, 11 cases;
grade 3: efficacy 63.7%, 8 cases), PIN (grade 2 or 3: effi-
cacy 100%, 1 case) or cancer (no cases).
Severe adverse events following immunization were re-
ported in two of the included RCTs [32, 33]. Because the
smaller [33] was composed of a subgroup of participants
from the larger RCT [32], all severe adverse events re-
ported in the former had already been included and re-
ported in the latter. Therefore, only data from the larger
RCT were considered here. During the entire study
period, 8 adverse events were observed in the vaccinated
group (2020 participants) and 11 events occurred in the
placebo group (2029 participants). This finding corre-
sponds to a risk ratio of 0.73 (95% CI 0.25–1.99) and a
risk difference of − 0.2 (95% CI −0.7 to 0.3). According
to the trial investigators, none of these adverse events
were judged to be vaccine-related.














Giuliano et al. 2011 [32] + + + + + + +
Palefsky et al. 2011 [33] + + + + + + +
Coskuner et al. 2014 [31]a + + – – + + +
NCT01461096 [26] + + + + + + +
+ low risk of bias, − high risk of bias
aControls received no vaccination, yet blinding was not possible
Table 4 Risk of bias in non-randomized studies










Swedish et al. 2012 [25]a + – ++ ++ – ++ ++ –
Swedish and Goldstone
2014 [34]a
+ – ++ ++ – ++ ++ –
Kahn et al. [24]b – – – – ++ – ++ ++ – –
++ low risk of bias, + moderate risk of bias, − serious risk of bias, – –- critical risk of bias
aUnclear selection into study; differences in follow-up time between groups; loss-to-follow up
bOnly unadjusted data available; unclear selection into study; loss-to-follow up; possible misclassification of intervention
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Evidence quality according to GRADE was judged
“high” only for the outcome condyloma acuminatum.
For five of the included outcomes (incident anogenital
infection, persisting oral infection, persisting anogenital
infection, AIN grade 2 and severe adverse events follow-
ing immunization), evidence quality was downgraded to
“moderate” due to serious imprecision (wide 95% CIs).
The outcome AIN grade 3 was judged to provide “low”
quality evidence due to very serious imprecision (very
wide 95% CI). Incident oral infection was assessed to
provide “very low” quality evidence due to the non-ran-
domized study design and serious imprecision. The evi-
dence quality for PIN grade 2/3 was judged to be “very
low” due to serious indirectness (the outcome in the
trial comprised penile, perineal and perianal neoplasia)
and very serious imprecision (see the GRADE evidence
profile in Additional file 3 for details).
Discussion
This systematic review of randomized and non-randomized
studies evaluated the efficacy, effectiveness and safety of
HPV vaccination in males. When vaccinating individuals ir-
respective of their HPV status, vaccination is moderately ef-
fective against genital HPV infection and high-grade anal
intraepithelial lesions. Higher vaccine efficacy was observed
in those participants who were naïve for the respective
HPV types assessed in the individual studies. No meaning-
ful estimate of vaccine efficacy could be calculated for
high-grade penile intraepithelial lesions, and no data were
available regarding vaccine efficacy or effectiveness against
anal, penile or head and neck squamous cell cancer. Due to
their imprecision of estimates, the GRADE evidence quality
was moderate to low for the majority of outcomes.
To our knowledge, this is the first systematic review
on the efficacy, effectiveness and safety of HPV
Table 5 Efficacy or effectiveness of vaccination against human papillomavirus in males: infections in participants irrespective of their
HPV status at enrolment








Giuliano et al. 2011 [32]a RCT 189/4070.0 pyrs 259/4014.2 pyrs NR NA 28.0% (12.9–40.7%)
HPV 18
Giuliano et al. 2011 [32]a RCT 89/4205.4 pyrs 133/4151.5 pyrs NR NA 33.9% (13.0–50.1%)
Persisting anogenital infection
HPV 16
Giuliano et al. 2011 [32]a RCT 71/4199.5 pyrs 131/4112.7 pyrs NR NA 46.9% (28.6–60.8%)
HPV 18
Giuliano et al. 2011 [32]a RCT 25/4267.0 pyrs 56/4210.1 pyrs NR NA 56.0% (28.8–73.7%)
Incident anal infection
HPV 16
Palefsky et al. 2011 [33]a RCT 40/615.7 pyrs 71/599.9 pyrs NR NA 45.1% (18.0–63.7%)
HPV 18
Palefsky et al. 2011 [33]a RCT 20/651.2 pyrs 39/641.3 pyrs NR NA 49.5% (11.3–72.1%)
Persisting anal infection
HPV 16
Palefsky et al. 2011 [33]a RCT 24/636.6 pyrs 51/622.3 pyrs NR NA 54% (23.9–72.9%)
HPV 18
Palefsky et al. 2011 [33]a RCT 7/668.4 pyrs 26/656.3 pyrs NR NA 73.6% (37.5–90.3%)
Incident oral infection
HPV 16 and/or HPV 18
Kahn et al. 2015 [24]a Cross-sectional study 0/23 9/48 NR NR 91% (−59–99.5%)
Persisting oral infection
NCT01461096 [26]b RCT 1/236 8/236 0.12 (0.02–0.98)c NR 88% (2–98%)
NA not applicable, NR not reported, pyrs person-years, VE vaccine efficacy or effectiveness
aVE as reported in the primary study
bVE calculated from unadjusted estimate
cHazard ratio (95% CI)
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vaccination in males. In contrast, at least seven systematic
reviews of studies assessing the effects of HPV vaccination
in females have been published demonstrating high
efficacy and effectiveness of HPV vaccination against in-
fection and dysplasia, particularly in HPV-naïve study par-
ticipants [35–41]. Considerable differences exist in the
body of evidence between male and female HPV vaccin-
ation regarding the primary study base. While our current
systematic review comprised data from about 5000
participants, randomized trials on HPV vaccination in fe-
males included more than 46,000 participants in total
[41]. Beyond study size, considerable differences exist
between HPV trials in males and females regarding the
validity of outcomes and evidence quality. For precancer-
ous lesions of the cervix (cervical intraepithelial neopla-
sia), robust data from the above-mentioned systematic
reviews show that vaccination against HPV prevents
high-grade lesions over a time period of more than 6
years. As shown in our systematic review, the evidence
base is weaker regarding precancerous lesions in males,
particularly for penile lesions. Furthermore, evidence on
efficacy, effectiveness and safety of HPV vaccination in
males is currently restricted to a period of 4 years after
vaccination. Similar to findings from HPV vaccination in
females, a considerably higher vaccine efficacy has been
found in men who were seronegative and PCR-negative at
study entry [41].
Our systematic review has several strengths. It was
conducted based on a comprehensive and published re-
view protocol, and internationally accepted tools for the
assessment of risk of bias were applied. We performed
an outcome-specific assessment of the available data and
assessed the quality of the body of evidence for each out-
come using the GRADE methodology. We performed a
comprehensive review by including different study de-
signs and populations (MSM as well as heterosexual
men). The limitations of this review mainly arise from
the limitations of the included primary studies. The two
major RCTs included here were designed to evaluate
compound endpoints comprising malignant and benign
lesions. Consequently, neither of these studies had enough
power to detect premalignant or malignant lesions as de-
fined in our protocol. Furthermore, the existing non-ran-
domized studies have a high risk of bias. A limitation of
our systematic review stems from the restriction of the
outcomes to clinical endpoints. For example, we did not
Table 6 Efficacy or effectiveness of vaccination against human papillomavirus in males: infections in participants who were
seronegative and PCR-negative at enrolment








Giuliano et al. (2011) [32]a RCT 62/2337.7 pyrs 103/2287.8 pyrs NR NA 41.1% (18.5–57.7%)
HPV 18
Giuliano et al. (2011) [32]a RCT 25/2441.3 pyrs 66/2440.6 pyrs NR NA 62.1% (39.2–77.1%)
Persisting anogenital infection
HPV 16
Giuliano et al. (2011) [32]a RCT 9/2382.4 pyrs 41/2312.9 pyrs NR NA 78.7% (55.5–90.9%)
HPV 18
Giuliano et al. (2011) [32]a RCT 1/2461.9 pyrs 25/2453.5 pyrs NR NA 96% (75.6–99.9%)
Incident anal infection
HPV 16
Palefsky et al. (2011) [33]a RCT 6/326 pyrs 25/322.8 pyrs NR NA 76.2% (40.7–92%)
HPV 18
Palefsky et al. (2011) [33]a RCT 0/346.3 pyrs 16/375.1 pyrs NR NA 100% (71.9–100%)
Persisting anal infection
HPV 16
Palefsky et al. (2011) [33]a RCT 1/331.5 pyrs 16/329.9 pyrs NR NA 93.8% (60.0–99.9%)
HPV 18
Palefsky et al. (2011) [33]a RCT 0/346.3 pyrs 10/376.2 pyrs NR NA 100% (51.5–100%)
NA not applicable, NR not reported, pyrs person-years, VE vaccine efficacy or effectiveness
aVE as reported in the primary study
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search for immunogenicity data and can therefore not
draw conclusions from studies that used them as surro-
gate markers for protection. A further limitation of our
systematic review may arise from the decision to focus on
all lesions rather than on type-specific lesions. This ap-
proach might lead to an underestimation of the efficacy
and effectiveness of the vaccine. However, our approach
was chosen since it is likely to consider clinical impact
and the patient perspective more appropriately than an
approach that focusses on type-specific lesions. For future
updates of this review, several strategies might be tested in
order to improve the specificity of the search results. One
could, for instance, use the “NOT” operator to exclude
certain types of articles that do not contain data (such as
comments or editorials) from the search. Furthermore, it
appears possible to focus the search on certain study types
(such as RCTs, cohort studies, case-control studies) that
are relevant for the PICO (Patient, problem or population;
Intervention; Comparison, control or comparator; Out-
come) question.When HPV status prior to vaccination is
not considered, efficacy of HPV vaccination in males is
moderate, particularly regarding incident infections, and
the corresponding confidence intervals are wide. In cases
where only HPV-naïve participants are vaccinated, the
vaccine efficacy estimates are higher, but the correspond-
ing confidence intervals are still wide. These wide confi-
dence intervals might be due at least partly to variations
in sampling techniques, because the sampling in men has
not been as standardized as it is in women [42], and the
main results on genital and anal infections came from
multicentre studies [32, 33]. However, the estimates re-
ported here might be conservative, given that data from
females suggest that the efficacy of HPV vaccination in-
creases with longer follow-up due to the effect on incident
but not prevalent infections [43].
Evidence on efficacy and effectiveness of HPV vaccin-
ation in males is particularly scarce regarding oral infec-
tions; only one RCT with a small number of events and
one small observational study with a high risk of bias re-
ported data on this outcome. However, supporting evi-
dence regarding vaccine effectiveness against oral HPV
infections comes from two sources. Using data from the
Table 7 Efficacy or effectiveness of vaccination against human papillomavirus in males: anogenital lesions in participants irrespective
of their HPV status at enrolment (corresponding to intention-to-treat analysis in RCTs)








Giuliano et al. 2011 [32]a RCT 24/4635.4 pyrs 72/4558.8 pyrs NR NA 67.2% (47.3–80.3%)
Coskuner et al. 2014
[31]b
RCT 45/91 35/80 1.26 (0.69–2.30) NR −26% (− 130 to 31%)
Anal
Palefsky et al. 2011 [33]a RCT 13/651.3 pyrs 31/664.2 pyrs NR NA 57.2% (15.9–79.5%)
Swedish & Goldstone
2014 [34]d, e
Cohort study 10/269.3 pyrs 37/604.3 pyrs 0.49 (0.24–0.98) 0.45 (0.22–0.92) 55% (8–78%)
Anal intraepithelial neoplasia grade 2
Palefsky et al. 2011 [33]a RCT 11/668 pyrs 29/671.5 pyrs NR NA 61.9% (21.4–82.8%)
Swedish et al. 2012 [25]c, e Cohort study 12/117.6 pyrs 35/222.8 pyrs 0.52 (0.27–1.0) 0.50 (0.26–0.98) 50% (2–74%)
Anal intraepithelial neoplasia grade 3
Palefsky et al. 2011 [33]a RCT 10/665.9 pyrs 19/672.8 pyrs NR NA 46.8% (−20 to 77.9%)
Anal cancer
Palefsky et al. 2011 [33] RCT 0/678.4 pyrs 0/694.8 pyrs NR NA –
Penile, perineal or perianal neoplasia grade 2 or 3
Giuliano et al. 2011 [32]a RCT 3/4663.1 pyrs 2/4628.6 pyrs NR NA −48.9% (− 1682.6 to 82.9%)
Penile, perineal or perianal cancer
Giuliano et al. 2011 [32] RCT 0/4670.6 pyrs 0/4630.5 pyrs NR NA –
aVE as reported in the primary study
bRecurrent lesions
cAll participants with a history of high-grade AIN (data for 24-month follow-up period); VE calculated from unadjusted estimate
d103/313 participants with recurrent lesions
eVE calculated from confounder-adjusted estimate
NA not applicable, NR not reported, pyrs person-years, VE vaccine efficacy or effectiveness
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Costa Rica Trial, Herrero et al. performed a post hoc
analysis of the impact of female vaccination with the bi-
valent vaccine on the prevalence of oral infections 4
years after the first vaccine dose. In this study, vaccine
effectiveness against oral HPV 16/18 infections was
93.3% (95% CI 63–100%) [44]. Furthermore, vaccinating
adult men with the quadrivalent vaccine was shown to
induce neutralizing antibodies in the oral cavity in 65.5%
(HPV 18) to 93.2% (HPV 16) of participants [45].
In a number of countries, HPV vaccination of girls
and women has already been implemented for nearly a
decade. If vaccination coverage in girls and women is
high enough, indirect (herd) protection of heterosex-
ual men can be achieved [46]. In the presence of herd
protection effects, it is not possible to study the effect-
iveness of HPV vaccination of men in isolation. There-
fore, we examined whether the results of the studies
included in our systematic review could have been af-
fected by HPV vaccination programs targeting girls
and women in the respective study countries. In fact,
five of the included studies were conducted in settings
where HPV vaccination of females was implemented
[24–26, 31, 34]. However, two of those studies in-
cluded MSM who do not benefit from such herd pro-
tection effects [25, 34]. For the remaining three
studies one cannot exclude the possibility that herd
protection effects might have slightly influenced the
respective study estimates.
Conclusions
This systematic review shows that the currently avail-
able evidence on the efficacy/effectiveness and safety of
HPV vaccination in males is limited due to the small
number of relevant studies, imprecise estimates and
lack of data for some critical outcomes. Vaccine effect-
iveness drops markedly in individuals who are already
infected with the corresponding HPV type. This sup-
ports a recommendation for early vaccination of boys
with the goal of establishing optimal vaccine-induced
protection before the onset of sexual activity. This
might not be a realistic option when implementing a
program that intends to target only high-risk males
such as MSM or HIV-positives. On the other hand,
even if the relative vaccine efficacy in such a population
with a high prevalence of infection is low, the impact of
the vaccine in MSM may be much higher because of
the high absolute risk in this group. While the limita-
tions of the evidence base point to a need for further
studies in men, it is important to bear in mind that the
results of population-based studies might be difficult to
interpret in the presence of the above-mentioned herd
protection effects. Furthermore, mathematical model-
ling studies will still be needed to assess the effects of
adding males to existing HPV vaccination programs in
more detail. The two available studies with vaccination
of HPV-naïve males showed high efficacy for reducing
dysplasia.
Table 8 Efficacy or effectiveness of vaccination against human papillomavirus in males: anogenital lesions in participants who were
seronegative and PCR-negative at enrolment








Giuliano et al. (2011) [32]a RCT 3/2830.9 pyrs 28/2813.9 pyrs NR NA 89.4% (65.5–97.9%)
Anal
Palefsky et al. (2011) [33]a RCT 0/386.8 pyrs 6/418.2 pyrs NR NA 100% (8.2–100%)
Anal intraepithelial neoplasia grade 2
Palefsky et al. (2011) [33]a RCT 2/384.5 pyrs 9/418.6 pyrs NR NA 75.8% (−16.9 to 97.5%)
Anal intraepithelial neoplasia grade 3
Palefsky et al. (2011) [33]a RCT 2/385.4 pyrs 6/419.7 pyrs NR NA 63.7 (−103 to 96.4%)
Anal cancer
Palefsky et al. (2011) [33] RCT 0/386.8 pyrs 0/421.1 pyrs NR NA –
Penile, perineal or perianal neoplasia grade 2 or 3
Giuliano et al. (2011) [32]a RCT 0/2833.3 pyrs 1/2824.7 pyrs NR NA 100% (− 3788.2 to 100%)
Penile, perineal or perianal cancer
Giuliano et al. (2011) [32] RCT 0/2833.3 pyrs 0/2826.2 pyrs NR NA –
NA not applicable, NR not reported, pyrs person-years, VE vaccine efficacy or effectiveness
aVE as reported in the primary study
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